Legend Biotech Corporation LEGN
Set alert
At close · Nov 2
After hours · Nov 2, 6:42 PM ET
- YTD
- -2.94%
- 1 year
- -34.88%
- Open
- 21.78
- Prev close
- 21.63
- Mkt cap
- 4.10B
- Vol
- 1.13M
- Avg vol
- 2.13M
- EPS
- -0.51
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 21.00
- High
- 21.79
- Forward P/E
- 20.10
- Beta
- 0.55
- Short ratio
- 6.10
- Inst. own
- 55.79%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 10, 2026
- 50-d avg
- 19.55
- 200-d avg
- 22.13
- 1y target
- 45.62
News
4 days ago zacks.com
Legend Biotech Corporation Sponsored ADR (LEGN) Recently Broke Out Above the 200-Day Moving Average
From a technical perspective, Legend Biotech Corporation Sponsored ADR (LEGN) is looking like an interesting pick, as it just reached a key level of support. LEGN recently overtook the 200-day moving…
6 days ago zacks.com
Legend Biotech Corporation Sponsored ADR (LEGN) Crossed Above the 50-Day Moving Average: What That Means for Investors
After reaching an important support level, Legend Biotech Corporation Sponsored ADR (LEGN) could be a good stock pick from a technical perspective. LEGN surpassed resistance at the 50-day moving…
6 days ago globenewswire.com
Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results
BRIDGEWATER N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m.
1 week ago seekingalpha.com
Legend Biotech: Carvykti Makes Billions, But The Profits Are Elusive
CARVYKTI's quarterly sales reached $710 million, but Legend's high expenses have kept recurring profitability low. Q2 results show improving operating leverage, with collaboration revenue growing…
2 weeks ago globenewswire.com
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known…
-
2 weeks ago benzinga.com
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $68
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $74 to $68.
-
3 weeks ago benzinga.com
JP Morgan Maintains Neutral on Legend Biotech, Lowers Price Target to $33
JP Morgan analyst Jessica Fye maintains Legend Biotech (NASDAQ:LEGN) with a Neutral and lowers the price target from $35 to $33.
-
3 weeks ago benzinga.com
RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $56
RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $58 to $56.
1 month ago globenewswire.com
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
Annual program will award funding to early-career healthcare professionals advancing research, education, and innovation in multiple myeloma BRIDGEWATER, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) --…
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $65 price target.
1 month ago defenseworld.net
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Stock Has Consensus Price Target of $53.14 According to Analysts
Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN - Get Free Report) has been assigned a consensus rating of "Hold" from the fifteen brokerages that are currently covering the company,…
-
1 month ago benzinga.com
Legend Biotech Reports 50% Of CARTITUDE-2 Patients Remained Progression-Free At 5 Years After Single CARVYKTI Infusion
Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMMBRIDGEWATER, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) --…
1 month ago globenewswire.com
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM
1 month ago reuters.com
Legend Biotech taps Novartis veteran Zhang as CEO
Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective immediately, banking on an industry veteran to steer its expansion beyond blockbuster cancer…
1 month ago globenewswire.com
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that its Board of…
1 month ago wsj.com
Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July
Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.
-
1 month ago benzinga.com
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $74
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $78 to $74.
-
1 month ago benzinga.com
Legend Biotech To Present Data For Its CARTITUDE-2 Trial Of CARVYKTI At 23rd International Myeloma Society Annual Meeting
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that data from CARTITUDE-2 and real-world evidence will be presented at the 23rd…
1 month ago globenewswire.com
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
Updated long-term follow-up data will be presented from CARTITUDE-2 Cohort A in patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapy Real-world evidence and…
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $65 price target.
2 months ago globenewswire.com
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
BRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief…
2 months ago benzinga.com
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts changed outlooks on top stocks. Raymond James downgraded ONON, Deutsche Bank downgraded ATAI, BTIG downgraded APGE.
-
2 months ago benzinga.com
Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $49
Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and raises the price target from $48 to $49.
-
2 months ago benzinga.com
TD Cowen Maintains Hold on Legend Biotech, Lowers Price Target to $24
TD Cowen analyst Yaron Werber maintains Legend Biotech (NASDAQ:LEGN) with a Hold and lowers the price target from $29 to $24.
-
2 months ago benzinga.com
Oppenheimer Downgrades Legend Biotech to Perform, Lowers Price Target to $40
Oppenheimer analyst Trevor Allred downgrades Legend Biotech (NASDAQ:LEGN) from Outperform to Perform and lowers the price target from $75 to $40.
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $58
RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $59 to $58.
-
2 months ago benzinga.com
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $78
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $80 to $78.
2 months ago 247wallst.com
Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More
With all eyes locked on this morning's CPI release and the Strait of Hormuz nearly shut down, Wall Street analysts are already repositioning across hospitality, pharma, and tech before the market…
2 months ago seekingalpha.com
Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript
Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript
2 months ago 247wallst.com
Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus
Shares of Legend Biotech (NASDAQ:LEGN | LEGN Price Prediction) are climbing 6% to $21.88 Tuesday midday after the company reported Q2 2026 results that paired a solid revenue beat with the first…
2 months ago marketbeat.com
Legend Biotech Q2 Earnings Call Highlights
Legend Biotech NASDAQ: LEGN reported second-quarter 2026 results marked by continued global growth for CARVYKTI and the company's first quarter of company-wide profitability on both an IFRS and…
-
2 months ago benzinga.com
Legend Biotech Q2 Adj. EPS $0.16 Beats $0.07 Estimate, Sales $387.500M Beat $355.772M Estimate
Legend Biotech (NASDAQ:LEGN) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.07 by 100 percent. This is a 147.06 percent increase over losses of $(0.34)…
3 months ago benzinga.com
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold health care stocks present a buying opportunity. RSI indicator compares stock strength on up and down days, indicating short-term performance. Here's the latest list of oversold…
-
3 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $65 price target.
3 months ago defenseworld.net
Legend Biotech (NASDAQ:LEGN) Shares Gap Down After Analyst Downgrade
Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN - Get Free Report)'s share price gapped down prior to trading on Monday after Royal Bank Of Canada lowered their price target on the stock from…
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $59
RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $63 to $59.
-
3 months ago benzinga.com
Legend Biotech CEO Ying Huang Steps Down, Alan Bash Named Interim CEO
Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and…
3 months ago globenewswire.com
Legend Biotech Announces CEO Transition
BRIDGEWATER, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced that Ying Huang,…
3 months ago seekingalpha.com
Legend Biotech: Why I'm Ready To Go Long Again
On July 15, J&J, a Legend Biotech Corporation partner, announced continued strong demand for Carvykti. Sales of this CAR-T cell therapy were $657 million in the second quarter, up 10.1%…
-
3 months ago benzinga.com
UBS Downgrades Legend Biotech to Neutral, Lowers Price Target to $28
UBS analyst Ashwani Verma downgrades Legend Biotech (NASDAQ:LEGN) from Buy to Neutral and lowers the price target from $49 to $28.
3 months ago benzinga.com
Top 3 Health Care Stocks That May Rocket Higher In July
Health care sector oversold - buying opportunities in undervalued companies. RSI compares stock strength on up/down days, below 30 is oversold.
-
3 months ago benzinga.com
JP Morgan Reinstates Neutral on Legend Biotech, Announces $35 Price Target
JP Morgan analyst Jessica Fye reinstates Legend Biotech (NASDAQ:LEGN) with a Neutral and announces $35 price target.
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $63
RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $64 to $63.
4 months ago benzinga.com
Why Is Legend Biotech Stock Falling Thursday?
Legend Biotech (LEGN) shares drop in premarket trading after pricing a $226M public offering. Get the latest technical levels here.
4 months ago benzinga.com
Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.35 each, shares down 9% in pre-market trading.
4 months ago benzinga.com
Why Smith & Wesson Brands Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Smith & Wesson (SWBI) shares rose in pre-market trading after posting strong Q4 results, beating earnings and revenue estimates. Other gainers include LNKS, ADTX, and SPRO.
-
4 months ago benzinga.com
Legend Biotech Commences $225M Offering Of Its American Depositary Shares
Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that it has commenced an underwritten public offering of $225 million of…
-
4 months ago benzinga.com
Reported Sunday, Legend Biotech's LB2501 In Vivo CD19/CD20 Dual-Targeting CAR-T Achieves 100% ORR And 83.3% CR Rate At Dose Level 2 In Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 studySingle infusion of LB2501 generated…
-
5 months ago benzinga.com
UBS Maintains Buy on Legend Biotech, Raises Price Target to $49
UBS analyst Ashwani Verma maintains Legend Biotech (NASDAQ:LEGN) with a Buy and raises the price target from $31 to $49.
5 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today's Session
10 Health Care Stocks Whale Activity In Today's Session